


## Dr. Nicholas P Restifo

MD, Advisory Board, IMEL Biotherapeutics

**Oct 16, 2024 (Wed) 17:00-18:00**

**Venue: Seminar Room 103/107**

**Faculty of Medicine Bldg. A 1F (Bldg.No.5)**



### “Enhancing the Function of Tumor-Infiltrating Lymphocytes (TIL) for Cancer Immunotherapy”

T cell exhaustion and accelerated aging is a hallmark of most tumor-specific T cells, a critical component of the immune response to tumors. Tumor-specific T cells may accumulate at tumor sites because they experience migratory arrest and remain in proximity to tumor cells but are unable to exert effective anti-tumor activity. Despite this pervasive exhaustion, TIL can trigger objective clinical responses in a broad range of malignancies, including breast, colon, bile duct, lung, and HPV-associated cancers. I will review the cell intrinsic molecular and functional correlates of clinically effective TIL. A deeper understanding of the qualities of clinically effective TIL is guiding efforts to rejuvenate and re-functionalize these cells, which includes epigenetic interventions and repair or replacement of dysfunctional mitochondrial within TIL for use in treatment-refractory malignancies.



**Admission free.**  
**No advance registration required.**  
**Please mark your calendar and join us!**

Organized by  
Center for Cancer Immunotherapy and  
Immunobiology (CCII)  
[060office-ccii@mail2.adm.kyoto-u.ac.jp](mailto:060office-ccii@mail2.adm.kyoto-u.ac.jp)  
<https://www.ccii.med.kyoto-u.ac.jp/en/events/>